Information Provided By: 
Fly News Breaks for November 14, 2016
PBYI
Nov 14, 2016 | 13:30 EDT
JPMorgan analyst Cory Kasimov views the selloff today in shares of Puma Biotechnology as an overreaction. The diarrhea rates included in abstract posted today are worse than the last update, but the rates are equivalent to a median number of around 1 episode per patient in the first cycle of treatment, Kasimov tells investors in an intraday research note. He continues to consider neratinib an approvable drug based on currently available data.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
